Evidence map›Paper›PMID 26802434›Full record

ReviewDiabetic medicine : a journal of the British Diabetic Association2016

Personalized medicine in diabetes: the role of 'omics' and biomarkers.

E R Pearson

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diabetic medicine : a journal of the British Diabetic Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 3 pooled it
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Economics and Precision Medicine.Handbook of experimental pharmacology · 2023
    Article
  15. Review
  16. Article
  17. Pharmacogenetics of new classes of antidiabetic drugs.Bosnian journal of basic medical sciences · 2021
    Review
  18. Review
  19. Precision Health Care Elements, Definitions, and Strategies for Patients with Diabetes: A Literature Review.International journal of environmental research and public health · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

E R PearsonDivision of Cardiovascular and Diabetes Medicine, Medical Research Institute, University of Dundee, Dundee, UK.
University of Dundee · GB

Funding

Wellcome TrustWellcome Trust 102820/Z/13/Z
6 · The paper itself

Abstract

Personalized medicine, otherwise called stratified or precision medicine, aims to better target intervention to the individual to maximize benefit and minimize harm. This review discusses how diabetes aetiology, pathophysiology and patient genotype influence response to or side effects of the commonly used diabetes treatments. C-peptide is a useful biomarker that is underused to guide treatment choice, severe insulin deficiency predicts non-response to glucagon-like peptide-1 receptor agonists, and thiazolidinediones are more effective in insulin-resistant patients. The field of pharmacogenetics is now yielding clinically important results, with three examples outlined: sulphonylurea sensitivity in patients with HNF1A maturity-onset diabetes of the young; sulphonylurea sensitivity in patients with Type 2 diabetes with reduced function alleles at CYP2C9, resulting in reduced metabolism of sulphonylureas; and severe metformin intolerance associated with reduced function organic cation transporter 1 (OCT1) variants, exacerbated by drugs that also inhibit OCT1. Genome-wide approaches and the potential of other 'omics', including metagenomics and metabolomics, are then outlined, highlighting the complex interacting networks that we need to understand before we can truly personalize diabetes treatments.

Indexed as

BiomarkersCytochrome P-450 CYP2C9Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Genome-Wide Association StudyGenomicsHumansHypoglycemic AgentsInsulinMetabolomicsOrganic Cation Transporter 1Precision MedicineBiomarkersCYP2C9 protein, humanCytochrome P-450 CYP2C9Hypoglycemic AgentsInsulinOrganic Cation Transporter 1

Identifiers

PMID26802434
PMCPMC4879510
OpenAlexW2266754539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.